Profusa, Inc. (NASDAQ:PFSA) Short Interest Down 57.2% in June

Profusa, Inc. (NASDAQ:PFSA) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 123,461 shares, a decline of 57.2% from the May 31st total of 288,318 shares. Based on an average trading volume of 412,104 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.7% of the company’s stock are sold short.

Profusa Stock Down 0.3%

PFSA traded down $0.00 on Monday, reaching $0.11. The company’s stock had a trading volume of 881,967 shares, compared to its average volume of 3,859,487. The company has a market capitalization of $531,240.00, a price-to-earnings ratio of -0.00 and a beta of 0.35. Profusa has a fifty-two week low of $0.11 and a fifty-two week high of $180.00. The stock has a 50 day moving average of $0.39 and a two-hundred day moving average of $2.91.

Profusa (NASDAQ:PFSA) last released its quarterly earnings data on Friday, May 15th. The company reported ($2.05) earnings per share for the quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on PFSA shares. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Profusa in a research note on Wednesday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.